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The frequent association between COVID-19 and olfactory dysfunction is creating an 
unprecedented demand for a treatment of the olfactory loss. Systemic corticosteroids 
have been considered as a therapeutic option. However, based on current literature, we 
call for caution using these treatments in early COVID-19 related olfactory dysfunction 
since (1) evidence supporting their usefulness is weak; (2) the rate of spontaneous 
recovery of COVID-19 related olfactory dysfunction is high and (3) corticosteroids have 
well-known potential adverse effects. We encourage randomized placebo-controlled trials 
investigating the efficacy of systemic steroids in this indication. Based on current 
knowledge, we strongly emphasize to initially consider smell training, which has no known 











The high rate of patients experiencing COVID-19 related olfactory dysfunction (C19OD) 
(approximately 20% of COVID-19 patients are reported to have OD at 8 weeks after the onset 
of the disease1) and mental and physical burden induced by losing the sense of smell is 
creating an unprecedented demand for a treatment of the olfactory loss.  
In contrast to previously known, non-COVID-19 associated, postinfectious olfactory 
dysfunction where patients usually present for medical consultation months after the 
infectious event, C19OD patients are being seen earlier in the course of the disease at 
specialised smell and taste centers. The heightened attention to smell disorders and the 
pronounced fear that of COVID-19 associations, paired with the worries about recovery, may 
biases our approach to very early changes after postinfectious smell disorders. This presents 
a unique opportunity for an early intervention, but also raises the question whether such 
intervention is needed to increase the likelihood for olfactory recovery.  
C19OD likely results from two separate pathological processes. First, an obstructive 
inflammatory process blocking odorant access2 at an early stage of the disease; and second, a 
neurosensory post-infectious smell loss 3,4. 
Systemic corticosteroids (CS) are part of the ENT armamentarium in several inflammatory (i.e. 
chronic rhinosinusitis (CRS)) and sensorineural conditions (i.e. sudden sensorineural hearing 
loss (SSNHL) and idiopathic facial palsy). CS are also considered as neuroprotective agents in 
acute neurological conditions such as spinal cord injury. Consequently, systemic CS therapy 
has been considered as an option to treat C19OD5. However, it is important to consider the 
balance of risks and benefits of systemic CS. In the absence of data supporting the lack of 
major side effects of systemic CS in COVID-19 patients, several professional groups such as 
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EAACI6 have called for caution and recommended against the use of systemic CS in CRS during 
COVID-19. Moreover, the efficacy of CS in their classical neurological indications, such as 
SSNHL and acute spinal cord injury remains questionable7,8, and it is well know that their use 
is associated to potentially serious adverse effects8. Therefore, when considering whether 
such treatment should be used for C19OD, natural history and potential added benefit versus 
treatment risk must be carefully considered. 
As an expert group in clinical olfaction, we aim to briefly review and summarize evidence for 
and against CS treatment in C19OD based on current literature on COVID-19 and post-
infectious olfactory loss in general. 
Rate of COVID-19 related olfactory dysfunction and spontaneous recovery 
Recent meta-analyses have determined that the pooled frequency of OD in COVID-19 patients 
(either based on questionnaire or smell psychophysical tests) was 56%9-61%10. However, 
there is extremely high variability in the reported prevalence of this symptom, ranging from 
5%11 to 98%12.  
Similarly, documented rates of olfactory recovery amongst COVID-19 patients vary, most likely 
due to methodological discrepancies and sampling bias both between and within studies. 
However, in general there appears to be a high rate of recovery. At one month, authors found 
resolution rates of OD in 33%-96% of patients13-17. At 2 months, return to normal olfactory 
function was reported by 54% of patients18. Figure 1 details reported rates of OD as a function 
of time, based on self-assessment13-21. When assessing olfactory function based on 
psychophysical testing (Figure2), follow-up studies found a 63% rate of normosmia at 5 
weeks22, 54%-79% at 2 months 1,23,24; 86% at 3 months25 and 95% at 6 months21. Of note, the 
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rate of hyposmia in the general population is approximately 20%26,27. Although it is probable 
that a majority of patients reporting C19OD had normal olfaction at baseline, it cannot be 
ruled out that some were hyposmic at baseline and became alerted to it through COVID-
related public attention. 
Consequently, it appears from the current literature that C19OD is largely reversible for most 
affected patients in the short- to medium-term, while a significant minority progress to a 
persistent olfactory dysfunction characterized by hyposmia and, in many cases, parosmia, 
typical of a neural post-infectious OD28. 
Usefulness of CS in post-infectious olfactory dysfunction 
Although several studies have investigated the usefulness of CS administered through 
different formulations, routes and doses in patients with post-infectious olfactory dysfunction 
(PIOD), their general efficacy remains controversial29,30.  
A recent systematic evidence-based review investigated the use of CS in non-sinonasal OD30, 
and reported very weak evidence to support the use of systemic CS therapy (Level 4). Of note, 
it appears that topical CS sprays are not effective in non-sinonasal OD. The only evidence 
suggested that, in conjunction with olfactory training, nasal irrigation with budesonide has 
more favourable outcome than saline irrigation alone among patients with non-sinonasal 
OD31 (Level 1b). However, for this last study, results have not been interpreted as a function 
of the aetiology and it is difficult to generalise these results to the PIOD population. Another 
recent evidence-based review of treatment options for PIOD concluded that olfactory training 
is a recommendation for the treatment of PIOD; while systemic or topical steroids remain 
“optional” due to the lack of high-quality studies29.  
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It has been suggested that the favourable effect of CS in PIOD could be attributed to their 
effects on any underlying sinonasal inflammation30,32, theoretically resulting from mucosal 
effects of an upper respiratory tract infection. Thus, standard rhinological examination 
remains mandatory in patients with persistent olfactory loss and rhinosinusitis must be 
treated appropriately32,33.  
Importantly, although CS are often reported as having the potential to improve olfactory 
function, an animal study found that they may impair the neuronal regeneration at the level 
of the olfactory epithelium34. 
Therefore, there is low level evidence supporting the usefulness of CS in PIOD. Although level 
4 studies suggest that systemic CS could improve olfactory loss in PIOD (Level 4), there is a 
lack of high-quality studies, and no consensus can be reached at this time. On the other hand, 
there is also low evidence that CS are not effective or would impair olfactory function. 
Currently, CS are thus considered as a therapeutic option in selected patients and after 
personalised consideration of the potential risk5,29.  
In contrast, a currently accepted recommendation for the treatment of non-COVID-19 PIOD is 
smell training29,32, which has been shown with solid data29,32 to improve the recovery of PIOD.  
Systemic CS in COVID-19 patients  
At the onset of the pandemic, caution was recommended regarding the use of systemic CS 
due to the uncertainty regarding their immunosuppressive effect in COVID-19. However, they 
have turned out to constitute an important weapon against COVID-1935, and are 
recommended by the WHO in patients with severe and critical COVID-19 since they appear to 
reduce 28-day mortality36. Conversely, their use is not recommended in patients with mild 
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COVID-19 because it may increase the risk of death when administrated in non-severe COVID-
19 patients35,36 although this was a conditional recommendation based on low certainty 
evidence. Of note, it has been suggested that OD mainly affects patients with mild COVID-1937 
although this is still debated.  
A recent case report suggested that systemic CS could be effective for the treatment of 
C19OD38.  In this case report, a patient with anosmia received oral prednisolone, after failure 
of topical steroids, and was found to improve 6 days later. However, due to the rate of 
spontaneous recovery of C19OD, it cannot be ruled out that this is the natural evolution of 
the disease. Recently, a prospective study aimed to compare the efficacy of systemic CS 
associated with olfactory training (9 patients) to olfactory training alone (18 patients). The 
study found that only patients with combined therapy significantly improved olfactory 
function at 10 weeks follow-up. However, this has to be tempered by the fact that groups 
were not exactly similar. There was a higher number, and hence a higher variance, of patients 
in OT group. Also, patients receiving systemic CS were mainly anosmic and had therefore a 
higher chance to spontaneously improve their olfactory function. Moreover, there were no 
data regarding endoscopic examination and signs of nasal inflammation39. Another 
prospective study evaluating the rate of recovery of OD among COVID-19 patients found that 
neither topical (administrated in 71 patients) nor systemic CS (administrated in 58 patients) 
influenced the prognosis of olfactory recovery40. Therefore, there is currently no robust 
evidence supporting a potential effect of systemic CS in COVID-19 patients.  
QUESTIONS: 
Please answer to these questions: 
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Fully agreeing / partly agreeing / partly disagreeing / fully disagreeing 
- Systemic CS should be prescribed within 3 first weeks after the onset of COVID-19 OD 
(fully disagree) 
- Systemic CS should be considered as a first line treatment in COVID-19 OD 
(fully disagree) 
- There is no place for systemic CS in the treatment of COVID-19 OD 
(partly disagree) 
- In the lack of evidence, caution should prevail, and systemic CS should not be considered 
as a standard treatment in patients with COVID-19 OD 
-(fully agree) 





Acute C19OD and classical PIOD may exhibit some differences. For example, the high number 
of young and even adolescent patients experiencing impaired smell differentiates this 
condition from PIOD. However, C19OD and classical PIOD share many similarities including 
the temporary and more permanent form of OD, the frequent presence of parosmia, or the 
higher frequency of women affected. Extrapolation from classical PIOD may be tempting, but 
there is considerable bias in terms of the attention C19OD has received compared to previous 
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PIOD which was often disregarded by the medical community and perhaps unnoticed by 
patients.  
Current evidence supporting the usefulness of systemic CS in PIOD, and in particular for 
C19OD, is weak; while the rate of spontaneous recovery of C19OD is high. Considering the 
potential acute and possibly long-term adverse effects of CS, we suggest that caution must 
prevail, and systemic CS should not be considered as standard of care treatment intended for 
all patients having C19OD, in the early phase of the disease.  
To adequately stratify the risks and benefits related to systemic CS treatment, randomized 
placebo-controlled trials should be considered, and the question of the dose and duration of 
the treatment must be investigated. Moreover, it is notable, from our cumulative experience, 
that many C19OD patients complain of parosmia, frequently appearing several months after 
the acute infectious event28. Therefore, long-term follow-up studies are needed to evaluate 
whether CS treatment has the potential to decrease the risk of developing qualitative 
olfactory disorders. Given that many patients appear to recover without intervention, it will 
likely take large numbers of patients in such trials to demonstrate enhanced recovery with 
corticosteroid treatment, although given the recent increases in COVID19, recruitment may 
not be difficult, sadly. 
Considering the full spectrum of CS route of administration, an alternative is the use of topical 
CS. The option of nasal lavage with CS should also be investigated because it has been 
suggested that it could constitute an efficient and potentially less harmful alternative 
compared to systemic CS. However, their efficacy has not been specifically studied in PIOD 
patients and more data are needed to confirm their usefulness. Although we mentioned that 
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topical CS are typically not useful to treat PIOD, this may also be related to the fact that 
classical nasal spray administration does not reach the olfactory cleft. It has been suggested 
that the use of specific nasal cannulas for administration of sprays41 or application of nasal 
drops in the Kaiteki position42 could be effective for delivering medications into the olfactory 
cleft. Therefore, studies considering the effectiveness of different routes of administration of 
CS will be useful to define the most efficient option, if there is one.  
Conclusion 
Currently there is no evidence that any kind of CS treatment may substantially change the 
outcome of C19OD. In contrast there is sufficient evidence that even limited unjustified 
systemic CS treatment has harmful side effects such as long term increased risk for hip 
fractures or decompensating glaucoma43. In light of the huge number of patients possibly 
receiving steroids for C19OD, based on poor evidence, we call for caution using these 
treatments. At the same time, we encourage controlled studies investigating this issue.  
 
As an expert group we strongly emphasize to initially consider smell training44. Smell training 
has no known side effects and is low cost. Moreover, it is the only available treatment for PIOD 
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Rates of self-reported olfactory loss (absent or incomplete recovery) among COVID-19 
patients over time, based on available literature. References are mentioned at the top of 
the bars. Time is expressed as the average delay between the onset of the COVID-19 and 
rating of olfactory function. The dashed horizontal line represents the rate of hyposmia among 
the general population26. 
Figure 2 
Distribution of the rates of normosmia, hyposmia and anosmia among patients infected by 
SARS-CoV-2, at 4 weeks, 5 weeks, 2 months, 3 months and 6 months after the onset of the 
disease.  Olfactory function was assessed using diverse psychophysical methods (SST: Sniffin’ 
Sticks Test; SAOT: Self-administrated olfactory Test; CCCRC: Connecticut Chemosensory 
Clinical Research Center; B-SIT: Brief Smell Identification Test). References are reported at the 
top of the bar. The dashed horizontal line represents the rate of hyposmia among the general 
population26. 
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